ENVERIC BIOSCIENCES INC
Enveric Biosciences Inc (ENVB) is a micro‑capitalisation, clinical‑stage biopharmaceutical company. With a market capitalisation of around $2.20M, it should be viewed as a high‑risk, speculative investment. Enveric is known for pursuing novel therapeutic approaches; many activities are research‑ and trial‑oriented, so progress depends on regulatory approvals, clinical results and funding. For investors this means potential upside is paired with binary outcomes, thin liquidity and significant share price volatility. Financial statements may be limited and the company could need additional capital, which can dilute existing shareholders. If you consider this stock, treat it as a small, high‑risk holding within a diversified portfolio and be prepared for a long time horizon. This is general educational information, not financial advice — always verify company filings, recent news and consult a qualified financial adviser about suitability before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Enveric Biosciences stock, anticipating its price will rise significantly.
Financial Health
Enveric Biosciences is showing solid financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ENVB
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical outcomes matter
Progress hinges on trial results and regulatory decisions, which can move the share price sharply; outcomes are uncertain and binary.
High volatility potential
As a microcap, shares can rise or fall quickly on news or capital events; consider liquidity and position size carefully.
Research and regulation
Ongoing R&D and changing regulatory landscapes drive prospects; check filings and trial registries to follow developments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
